Cure My Disease

Don't miss your cure!

 Log in / Sign up

Silent artery disease exposed: 16,000-Person study aims to predict heart attacks before they happen

NCT ID NCT06692127

Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study scans over 16,000 adults aged 18 to 70 without known heart disease to find hidden (silent) plaque in their arteries using ultrasound and CT scans. The goal is to measure how common silent atherosclerosis is and build a risk calculator that combines imaging, lifestyle, and biomarkers to predict who will develop heart disease. Ultimately, this knowledge could lead to earlier, more personalized prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple screening tool that identifies people with hidden artery disease years before a heart attack or stroke, enabling early prevention.
What could go wrong
This is an observational study, not a treatment trial. The risk calculator will need further testing before it can be used in routine care, and it may not work equally well for all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

16,808 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Danish and Spanish adults 18-70 years of age of predominantly European ancestry without known atherosclerotic cardiovascular disease.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The study will include adults ≥18 to ≤70 years of age (1:1 sex ratio in each 10 years age strata). * Have not been diagnosed with ASCVD prior to inclusion into the study (participants with other cardiovascular diseases or predisposing factors are not excluded). * The participants will be recruited from sites in Denmark (n \~ 8,000) and Spain (n \~ 8,000). * Participants need to be capable and be able to read and understand Danish, English, Spanish or Arabic. Exclusion Criteria: * The participants will be excluded from the CTA with contrast if they have severe renal disease (eGFR \<30 ml), contrast allergies, pregnancy or other conditions excluding the performance of a CT-scan.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Cardiovascular diseases Subclinical atherosclerosis

Contacts and locations

Locations

  • Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)

    Madrid, E-28029, Spain

  • Herlev Hospital

    Herlev, 2730, Denmark

  • Regionshospitalet Gødstrup

    Herning, 7400, Denmark

  • Righospitalet - Glostrup Hospital

    Glostrup Municipality, 2600, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.